Ion Beam Applications SA designs, produces, and markets particle accelerator technology for medical and industrial applications. The company operates through four main segments: Proton Therapy, providing solutions for the diagnosis and treatment of cancer and other serious illnesses; Dosimetry & Quality Assurance, offering dosimetry equipment; RadioPharma Solutions, supplying cyclotron systems such as the Cyclone KIUBE for radiopharmaceutical production; and Industrial Solutions, which includes services like the sterilization of medical devices. IBA serves hospitals and healthcare providers globally, with offices in Canada, China, Germany, and the USA. The company is a certified B Corp and maintains a research division known as the IBA Discovery Lab focused on long-term innovation.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage iba-worldwide.com
Sector Healthcare IR page iba-worldwide.com/investor-relations
Tags
proton therapy, particle accelerators, dosimetry, radiopharmaceuticals, medical device sterilization, cyclotrons, quality assurance, IBA Discovery Lab, Cyclone KIUBE
Press page —

Metrics

Valuation  
Market cap € 500.262M
Market cap (USD) $ 548.687M
P/E 52.23
PEG 1.55
P/BV 4.36
P/S 1.00
P/OCF -47.24
P/FCF -27.78
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.5%
ROI 8.3%
ROIC 5.5%
Profit margin 1.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 33.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021
Revenue 498.157M 466.667M 361.27M 312.964M
Net profit 9.253M -9.11M 6.057M 3.879M
Free cash flow -18.01M -32.083M 14.383M 82.184M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Communiqué de Presse Information réglementée

IBA signe un contrat majeur pour une solution de stérilisation Be Efficient à haut débit en Allemagne Louvain-la-Neuve, Belgique, le 23 octobre 2026, 7h00 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et des solutions de faisceaux d’électrons et à rayons X pour l’irradiation industrielle de pointe, annonce aujourd’hui avoir signé un contrat avec un client, dont l’identité n’est pas dévoilée, pour la fourniture d’une solution de stérilisation par faisceau d’électrons (E-beam) Be Efficient entièrement intégrée, qui sera installée en Allemagne. Les technologies E-beam d’IBA permettent à différentes industries d’être plus résilientes et respectueuses de l’environnement en évitant le recours aux produits chimiques toxiques et aux matériaux radioactifs, ainsi que les déchets, problématiques de sécurité et risques qui leur sont associés. Principalement motivé par la conversion d’une stérilisation à l’EtO vers la stérilisation Ebeam, cet investissement marque une étape importante dans l’accélération de l’adoption de la technologie E-beam d’IBA et de la transition vers des solutions de stérilisation plus propres et plus durables, sans résidus chimiques ni émissions. Conçue comme une installation entièrement automatisée de nouvelle génération, la solution permettra d’atteindre un débit très élevé pour la stérilisation de produits médicaux, tout en offrant une grande efficacité opérationnelle et de faibles coûts d’exploitation. Sa conception intégrée fournira au client une plateforme rationalisée, flexible et évolutive pour une stérilisation avancée par faisceau d’électrons. L’entreprise prévoit de démarrer ses activités de stérilisation avec la solution Be Efficient en 2029. La solution Be Efficient combinera la technologie d’accélérateur Rhodotron® d’IBA avec un système complet de convoyage (Product Handling System - PHS), un système de contrôle de ligne de production Beagle® (Production Control System - PCS) et un système intégré de sécurité du bâtiment. IBA assurera l’ensemble du projet, comprenant la conception et l’ingénierie, la gestion de projet, la fabrication, l’installation, la mise en service et la formation. Thomas Servais, Président d’IBA Industrial Solutions, a commenté : « La signature de ce contrat constitue une réalisation importante pour IBA Industrial Solutions et une forte reconnaissance de notre technologie, de notre expertise et de notre vision à long terme. En fournissant une solution intégrée complète, de la conception et de l’ingénierie à l’installation, la mise en service et la formation, nous aidons l’un des acteurs les plus respectés au monde dans le secteur de la santé à renforcer ses capacités de stérilisation grâce à une installation hautement automatisée de nouvelle génération. Ce projet combine un débit exceptionnel, une grande efficacité opérationnelle et des coûts d’exploitation réduits, établissant une nouvelle référence en matière de performance et renforçant la position de leader d’IBA dans les solutions avancées de stérilisation par faisceau d’électrons. » Communiqué de presse | 23/10/2026 IBA | Ion Beam Applications SA

Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon VAT : BE 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 [email protected] | iba-worldwide.com

1

Communiqué de Presse Information réglementée

Le prix habituel d’une solution d’irradiation Be Efficient se situe entre 11 millions et 18 millions d’euros, selon la configuration et les options. FIN À propos d'IBA IBA (Ion Beam Applications S.A.) est le leader mondial dans la technologie d’accélération de particules. La société est le principal fournisseur d’équipements et de services dans les domaines de la protonthérapie, considérée comme l’une des formes les plus avancées de radiothérapie disponibles aujourd'hui, de la stérilisation industrielle, les radiopharmaceutiques et la dosimétrie. La société, dont le siège social est situé à Louvain-la-Neuve, en Belgique, emploie environ 2300 personnes dans le monde. IBA est une entreprise certifiée B Corporation (B Corp) qui répond aux plus hauts standards de performance sociale et environnementale. La société est cotée à la bourse paneuropéenne EURONEXT. (IBA: Reuters IBAB.BR et Bloomberg IBAB.BB). Pour plus d’informations : www.iba-worldwide.com

Subject: Bull 2 Bear 0 Order/contract

Press Release

Regulated information

IBA signs major contract for a high-throughput Be Efficient sterilization solution in Germany Louvain-la-Neuve, Belgium, October 23, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today that it has signed a contract with an undisclosed customer for the delivery of a fully integrated Be Efficient electron beam (E-beam) sterilization solution to be installed in Germany. IBA E-beam technologies enable various industries to be significantly more resilient and environmentally friendly by avoiding toxic chemicals and radioactive materials, and their associated waste, safety issues and hazards. Primarily driven by the conversion of a product portfolio from EtO to E-beam sterilization, this investment marks an important step in accelerating the adoption of IBA’s E-beam technology and the transition towards cleaner, more sustainable sterilization solutions with no chemical residues or emissions. Designed as a fully automated, next-generation facility, the solution will enable very high throughput for the sterilization of medical products while supporting high operational efficiency and low operating costs. Its integrated design will provide the customer with a streamlined, flexible and scalable platform for advanced electron beam sterilization. The company expects to start sterilization activities with the Be efficient solution in 2029. The Be Efficient solution will combine IBA’s Rhodotron® accelerator technology with a comprehensive conveyor system (Product Handling System - PHS), a Beagle® production line control system (PCS), and an integrated building safety system. IBA will provide the complete project scope, encompassing design and engineering, project management, manufacturing, installation, commissioning, and training. Thomas Servais, President of IBA Industrial Solutions, commented: “Securing this contract is a significant achievement for IBA Industrial Solutions and a strong endorsement of our technology, expertise, and long-term vision. By providing a complete integrated solution, from design and engineering through installation, commissioning, and training, we are helping one of the world’s most respected healthcare industry players enhance its sterilization capabilities with a highly automated, next-generation facility. This project combines exceptional throughput, operational efficiency, and reduced operating costs, setting a new benchmark for performance and reinforcing IBA’s leadership in advanced electron beam sterilization solutions.” The typical price for a Be-Efficient irradiation solution ranges from € 11 million to EUR 18 million depending on the configuration and options. END

Press release |

October 23, 2026

IBA | Ion Beam Applications SA Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 [email protected] | iba-worldwide.com

1

Press Release

Regulated information

About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

Subject: Bull 3 Bear 0 Clinical/regulatory

Press Release

First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announced that the first patient has been treated in the C-FLASH-01 clinical trial (NCT07644585), the first human feasibility study investigating ConformalFLASH®1 proton therapy, at Penn Medicine under an Investigational Device Exemption (IDE) authorized by the U.S. Food and Drug Administration (FDA). The study evaluates the feasibility of delivering fractionated ConformalFLASH® proton therapy using Bragg peak proton beams in patients requiring re-irradiation for head and neck cancer. The first treatment marks an important milestone for FLASH radiotherapy and for IBA, as sponsor of this clinical trial. It reflects the company’s expanding role in generating clinical evidence for proton therapy innovation and bringing ConformalFLASH® closer from bench to bedside. ConformalFLASH® is designed to combine the physical precision of proton therapy with ultra-high dose rate delivery capabilities to support clinical investigation of FLASH radiotherapy. By leveraging the Bragg peak and proprietary ConformalFLASH® technologies, the approach aims to deliver highly conformal treatments at ultra-high dose rates associated with FLASH delivery. The potential clinical benefits of this approach remain under investigation. Olivier Legrain, Chief Executive Officer of IBA, commented: "For nearly forty years, IBA has helped pioneer particle accelerator technologies that have transformed cancer care. Today, we are reaching another important milestone. With C-FLASH-01, IBA is not only providing the technology enabling innovation, but also actively supporting its clinical evaluation through this sponsored clinical trial. This reflects our commitment to helping shape the future of proton therapy, working alongside leading clinical partners to bring promising innovations from the laboratory to clinical practice." This first treatment is supported by a strong ecosystem of specialized collaborators, each contributing key capabilities: RaySearch Laboratories provides a research version of its FLASH treatment planning system; 3D Systems supports the 3D printing of patient-specific devices, including the ConformalFLASH® Energy Modulator (CEM); .decimal supplies precision-milled patient-specific apertures; and IBA Dosimetry develops FLASH-enabled dosimetry solutions, including FLASH Lynx and MatriXX Air. The milestone demonstrates how complementary clinical, technological and treatment-planning expertise can help translate innovation from research into clinical evaluation. For IBA, the evidence generated through C-FLASH-01 may help inform the future development of ConformalFLASH® technology and its potential integration into clinical proton therapy workflows. 1

ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development

Press release |

21/10/2026

IBA | Ion Beam Applications SA Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 [email protected] | iba-worldwide.com

1

Press Release

ENDS

Prompts

Ion Beam Applications SA (ticker IBAB), listed in Belgium.

ETFs Holding Ion Beam Applications SA

ETF Weight in ETF Shares Market value As of
AVDV 0.01% 149,590 $ 2.743M Nov 16, 2026
DFIS 0.00% 10,213 $ 194.172K Nov 12, 2026
DFAX 0.00% 3,444 $ 65.478K Nov 12, 2026
DXIV 0.00% 29 $ 551.35 Nov 12, 2026
DFAI 0.00% 1,459 $ 27.739K Nov 12, 2026
DFSI 0.00% 71 $ 1,349.87 Nov 12, 2026
AVDE 0.00% 2,121 $ 38.89K Nov 16, 2026